Self-immolative anthracycline prodrugs for suicide gene therapy

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2485-2489

  Niculescu Duvaz, Ion ^a   Niculescu Duvaz, Dan ^a   Friedlos, Frank ^a   Spooner, Robert ^a   Martin, Janet ^a   Marais, Richard ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOXYPEPTIDASE G2; DAUNORUBICIN DERIVATIVE; DOXORUBICIN DERIVATIVE; PRODRUG;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG HALF LIFE; GENE ACTIVATION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; SUICIDE GENE;

ANTINEOPLASTIC AGENTS; CELL MEMBRANE; DAUNORUBICIN; DOXORUBICIN; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; HUMANS; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0033168032     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980696v     Document Type: Article

References (35)

1. Bridgewater, G.; Springer, C. J.; Knox, R.; Minton, N.; Michael, P.; Collins, M. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 1995, 31A, 2362-2370.
2. Marais, R.; Spooner, R. A.; Light, Y.; Martin, J.; Springer, C. J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996, 56, 4735-4742.
3. Huber, B. A.; Richards, C. A.; Krenitsky, T. A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8039-8043.
4. Niculescu-Duvaz, I.; Spooner, R. A.; Marais, R.; Springer, C. J. S. Gene-directed enzyme prodrug therapy. Bioconjugate Chem. 1998, 9, 4-22.
5. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Friedlos, F.; Martin, J.; Spooner, R.; Davies, L.; Marais, R.; Springer, C. J. Self-immolative mustard prodrugs for suicide gene therapy. J. Med. Chem. 1998, 41, 5297-5309.
6. Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Searle, F.; Bisset, G. M. F.; Jarnian, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 1990, 33, 677-681.
7. Dowell, R.; Springer, C. J.; Davies, D. H.; Hadley, E. M.; Burke, P. J.; Boyle, F. T.; Melton, R. G.; Connors, T. A.; Blakey, D. C.; Mauger, A. B. New mustards prodrugs for antibody-directed enzyme prodrug therapy: alternative for the amide link. J. Med. Chem. 1996, 39, 1100-1105.
8. Springer, C. J.; Dowell, R. L.; Burke, P. J.; Hadley, E.; Davies, D. H.; Blakey, D. C.; Melton, R. G.; Niculescu-Duvaz, I. Optimization of alkylating prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J. Med. Chem. 1995, 38, 5051-5065.
9. Marais, R.; Spooner, R. A.; Stribbling, S. M.; Light, Y.; Martin, J.; Springer, C. J. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnol 1997, 15, 1373-1377.
10. Weiss, R. B.; Savory, G.; Clagget-Carr, K.; Russo, M.; Leyland-Jones, B. Anthracyclines analogues: past, present and future. Cancer Chemother. Pharmacol. 1986, 18, 185-197.
11. Grever, R.; Chabner, B. A. Cancer drug discovery and development, 5th ed.; Lipincott-Raven: New York, 1997; Vol. I.
12. Senter, P. D. Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy. FASEB J. 1990, 4, 188-193.
13. Andrianomenjanahary, S.; Dong, X.; Florent, J. C.; Gaudel, G.; Gesson, J. P.; Jacquesy, J. C.; Koch, M.; Michel, S.; Mondon, M.; Monneret, C.; Petit, P.; Renoux, B.; Tillequin, F. Synthesis of novel targeted pro-drugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate (Part 1). Bioorg. Med. Chem. Lett. 1992, 2, 1093-1096.
14. Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Petit, P.; Renoux, B.; Andrianomenjanahary, S.; Dufat-Trinh Van, H.; Koch, M.; Michel, S.; Tillequin, F.; Florent, J. C.; Monneret, C.; Bosslet, K.; Czech, J.; Hoffmann, D. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Des. 1994, 9, 409-423.
15. Azoulay, M.; Florent, J. C.; Monneret, C.; Gesson, G. P.; Jacquesy, G. P.; Tillequin, F.; Koch, M.; Bosslet, K.; Czech, J.; Hoffman, D. Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti-Cancer Drug Des. 1996, 10, 441-450.
16. Haisma, H. J.; Boven, E.; van Muijen, M.; de Jong, J.; van der Vygh, W. J. F.; Pinedo, H. M. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for the specific treatment of cancer. Br. J. Cancer 1992, 66, 474-478.
17. Haisma, H. J.; Van Muijen, M.; Pinedo, H. M.; Boven, E. Comparison of two anthracycline-based produgs for activation by a monoclonal antibody-β-glucuronidase conjugate in specific treatment of cancer. Cell Biophys. 1994, 24/25, 185-192.
18. Bosslet, K.; Czech, J.; Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 1994, 54, 2151-2159.
19. Leenders, R. G.; Scheren, H. W. Synthesis and evaluation of novel daunomycin-phosphate, sulfate, β-glucuronide and β-glucoside prodrugs for application in ADEPT. Bioorg. Med. Chem. Lett. 1995, 5, 2975-2980.
20. Bakina, E.; Zheng, W.; Rosenblum, M.; Farquhar, D. Intensely cytotoxic anthracycline prodrugs: Glucuronides. J. Med. Chem. 1997, 40, 4013-4018.
21. Farquhar, D.; Cherif, A.; Bakina, E.; Nelson, J. A. Intensely potent doxorubicin analogues: Structure-activity relationship. J. Med. Chem. 1998, 41, 965-972.
22. Jungheim, L. N.; Shepherd, T. A.; Kling, J. K. Synthesis of a cephalosporin-doxorubicin antitumor prodrug: A substrate for an antibody-targeted enzyme. Heterocycles 1993, 35, 339-348.
23. Svensson, H. P.; Vrudhula, V. M.; Emswiler, J. E.; MacMaster, J. F.; Cosand, W. L.; Senter, P. D.; Wallace, P. M. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res. 1995, 55, 2357-2365.
24. Vrudhula, V. M.; Svensson, H. P.; Senter, P. D. Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-β-lactamaee conjugates. J. Med. Chem. 1995, 38, 1380-1385.
25. Meyer, D. L.; Law, K. L.; Payne, J. K.; Mikolajczyk, S. D.; Zarrinmayeh, H.; Jungheim, L. N.; Kling, J. K.; Shepherd, T. A.; Starling, J. J. Site-specific prodrug activation by antibody-β-lactamaae conjugates: Preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Bioconjugate Chem. 1995, 6, 440-446.
26. Senter, P. D.; Svensson, H. P.; Schreiber, G. J.; Rodriguez, G. L.; Vrudhula, V. M. Poly(ethylene glycol)-doxorubicin conjugates containing β-lactamase-sensitive linkers. Bioconjugate Chem. 1995, 6, 389-394.
27. Kerr, D. E.; Schreiber, G. J.; Vrudhula, V. M.; Svensson, H. P.; Hellstrom, I.; Hellstrom, K. E.; Senter, P. D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 1995, 55, 3558-3563.
28. Rodrigues, M. L.; Presta, L. G.; Kotts, C. E.; Wirth, C.; Mordenti, C.; Osaka, G.; Wong, W. T.; Nuijens, A.; Blackburn, B.; Carter, P. Development of a humanized disulfide-stabilized anti-p185HER Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 1995, 55, 63-70.
29. Kerr, D. E.; Senter, P. D.; Burnett, P. D.; Hirschberg, D. L.; Hellstrom, I.; Hellstrom, K. E. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 1990, 31, 202-206.
30. Vrudhula, V. M.; Senter, P. D.; Fischer, K. J.; Wallace, P. M. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G-amidase conjugate. J. Med. Chem. 1993, 36, 919-923.
31. Wakselman, M. 1,4 and 1,6 eliminations from hydroxy- and amino-substituted benzyl systems: chemical and biochemical applications. N. J. Chim. 1983, 7, 439-447.
32. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 1981, 24, 479-480.
33. Senter, P. D.; Pearce, W. E.; Greenfield, R. S. Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J. Org. Chem. 1990, 55, 2975-2978.
34. Honda, M.; Morita, H.; Nagakura, I. Deprotection of allyl groups with sulfinic acids and palladium catalyst. J. Org. Chem. 1997, 62, 8932-8936.
35. Mistry, P.; Kelland, L. R.; Abel, G.; Sidhar, S.; Harrap, K. R. The relationships between glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer 1991, 64, 215-220.